Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California. more
Time Frame | APLM | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.47% | -3.39% | -3.47% |
1-Month Return | -59.33% | -3.25% | -0.29% |
3-Month Return | -37.87% | -11.61% | 4.5% |
6-Month Return | -61.7% | -5.89% | 6.91% |
1-Year Return | -89.75% | 2.65% | 23.79% |
3-Year Return | -99.2% | 0.56% | 28.43% |
5-Year Return | -99.2% | 34.63% | 83.64% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | 1.84M | 2.00K | 323.00K | 821.00K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.11,"profit":true},{"date":"2022-12-31","value":17.57,"profit":true},{"date":"2023-12-31","value":44.67,"profit":true}] | |
Cost of Revenue | 609.00K | 681.00K | 775.00K | 694.00K | [{"date":"2020-12-31","value":78.58,"profit":true},{"date":"2021-12-31","value":87.87,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.55,"profit":true}] | |
Gross Profit | 1.23M | (679.00K) | (452.00K) | 127.00K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-55.25,"profit":false},{"date":"2022-12-31","value":-36.78,"profit":false},{"date":"2023-12-31","value":10.33,"profit":true}] | |
Gross Margin | 66.87% | (33950.00%) | (139.94%) | 15.47% | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-50773.07,"profit":false},{"date":"2022-12-31","value":-209.28,"profit":false},{"date":"2023-12-31","value":23.13,"profit":true}] | |
Operating Expenses | 40.75M | 50.27M | 44.39M | 54.14M | [{"date":"2020-12-31","value":75.28,"profit":true},{"date":"2021-12-31","value":92.86,"profit":true},{"date":"2022-12-31","value":81.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (74.08M) | (91.75M) | (240.21M) | (54.83M) | [{"date":"2020-12-31","value":-7408500000,"profit":false},{"date":"2021-12-31","value":-9175100000,"profit":false},{"date":"2022-12-31","value":-24021100000,"profit":false},{"date":"2023-12-31","value":-5483400000,"profit":false}] | |
Total Non-Operating Income/Expense | (37.78M) | (44.14M) | (196.41M) | (117.15M) | [{"date":"2020-12-31","value":-3778300000,"profit":false},{"date":"2021-12-31","value":-4414200000,"profit":false},{"date":"2022-12-31","value":-19640700000,"profit":false},{"date":"2023-12-31","value":-11715400000,"profit":false}] | |
Pre-Tax Income | (74.91M) | (94.80M) | (240.81M) | (172.59M) | [{"date":"2020-12-31","value":-7490500000,"profit":false},{"date":"2021-12-31","value":-9479600000,"profit":false},{"date":"2022-12-31","value":-24081000000,"profit":false},{"date":"2023-12-31","value":-17259100000,"profit":false}] | |
Income Taxes | (85.00K) | 1.00K | 1.00K | 10.00K | [{"date":"2020-12-31","value":-850,"profit":false},{"date":"2021-12-31","value":10,"profit":true},{"date":"2022-12-31","value":10,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | (74.82M) | (94.80M) | (240.81M) | (172.60M) | [{"date":"2020-12-31","value":-7482000000,"profit":false},{"date":"2021-12-31","value":-9479700000,"profit":false},{"date":"2022-12-31","value":-24081100000,"profit":false},{"date":"2023-12-31","value":-17260100000,"profit":false}] | |
Income From Continuous Operations | (74.82M) | (94.80M) | (240.81M) | (172.60M) | [{"date":"2020-12-31","value":-7482000000,"profit":false},{"date":"2021-12-31","value":-9479700000,"profit":false},{"date":"2022-12-31","value":-24081100000,"profit":false},{"date":"2023-12-31","value":-17260100000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (74.82M) | (94.80M) | (240.81M) | (172.60M) | [{"date":"2020-12-31","value":-7482000000,"profit":false},{"date":"2021-12-31","value":-9479700000,"profit":false},{"date":"2022-12-31","value":-24081100000,"profit":false},{"date":"2023-12-31","value":-17260100000,"profit":false}] | |
EPS (Diluted) | - | (0.03) | (0.05) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3,"profit":false},{"date":"2022-12-31","value":-5.44,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
APLM | |
---|---|
Cash Ratio | 2.05 |
Current Ratio | 2.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
APLM | |
---|---|
ROA (LTM) | -62.74% |
ROE (LTM) | -149.31% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
APLM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.40 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.60 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
APLM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 4.14 |
P/B | 0.42 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Apollomics Inc. Class A Ordinary Shares (APLM) share price today is $8.255
Yes, Indians can buy shares of Apollomics Inc. Class A Ordinary Shares (APLM) on Vested. To buy Apollomics Inc. Class A Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APLM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Apollomics Inc. Class A Ordinary Shares (APLM) via the Vested app. You can start investing in Apollomics Inc. Class A Ordinary Shares (APLM) with a minimum investment of $1.
You can invest in shares of Apollomics Inc. Class A Ordinary Shares (APLM) via Vested in three simple steps:
The 52-week high price of Apollomics Inc. Class A Ordinary Shares (APLM) is $105. The 52-week low price of Apollomics Inc. Class A Ordinary Shares (APLM) is $6.5.
The price-to-earnings (P/E) ratio of Apollomics Inc. Class A Ordinary Shares (APLM) is
The price-to-book (P/B) ratio of Apollomics Inc. Class A Ordinary Shares (APLM) is 0.42
The dividend yield of Apollomics Inc. Class A Ordinary Shares (APLM) is 0.00%
The market capitalization of Apollomics Inc. Class A Ordinary Shares (APLM) is $16.52M
The stock symbol (or ticker) of Apollomics Inc. Class A Ordinary Shares is APLM